8 targeted drugs for treatment of the Chronic lymphocytic leukemia(CLL)

Date:2023-04-18 Views: 437 Times

Chronic lymphocytic leukemia (CLL) is a type of blood cancer that begins in the bone marrow,Can progress either slowly or quickly depending on the form it takes.Current therapies do not offer patients a cure for CLL, but there are treatments that help manage the disease. Chemotherapy and drug therapy, including targeted therapy and monoclonal antibody therapy

Ibrutinib[1]

Ibrutinib is used for the treatment of patients with chronic lymphocytic leukemia (CLL), including those with 17p deletion. It is a Bruton's tyrosine kinase (BTK) inhibitor, which blocks the growth of cancer cells.

Approval Statushttps://medlineplus.gov/druginfo/meds/a614007.html
Instructions for use:dosing, indications, interactions...etc.https://reference.medscape.com/drug/imbruvica-ibrutinib-999896
REFERENCE

Venetoclax[2]

Venetoclax is used for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), either as a single agent or in combination with other medications. It is a BCL-2 inhibitor, which helps to induce apoptosis in cancer cells.

Approval Statushttps://forum.bloodcancer.org.uk/t/venetoclax-with-obinutuzumab-for-cll/3828?gclid=CjwKCAjw3POhBhBQEiwAqTCuBslEqQ5jDOoWl7XBOztps5ltiO3K2mc2pT12nvtxxAQzgYDhMC4lLBoC6yUQAvD_BwE
Instructions for use:dosing, indications, interactions...etc.https://www.medscape.com/viewarticle/975652
REFERENCE

Acalabrutinib[3]

Acalabrutinib is used for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is a Bruton's tyrosine kinase (BTK) inhibitor that blocks the growth of cancer cells.

Approval Statushttps://medlineplus.gov/druginfo/meds/a618004.html
Instructions for use:dosing, indications, interactions...etc.https://reference.medscape.com/drug/calquence-acalabrutinib-1000209
REFERENCE

Zanubrutinib[4]

Zanubrutinib is a prescription medicine used to treat adults with:

  • Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
  • Waldenström's macroglobulinemia (WM).
  • Mantle cell lymphoma (MCL) who have received at least one prior treatment for their cancer.
  • Marginal zone lymphoma (MZL) when the disease has come back or did not respond to treatment and who have received at least one certain type of treatment.
Approval Statushttps://www.cancer.gov/news-events/cancer-currents-blog/2023/fda-zanubrutinib-cll-sll
Instructions for use:dosing, indications, interactions...etc.https://medlineplus.gov/druginfo/meds/a620009.html
REFERENCE

Idelalisib[5]

Idelalisib is a PI3Kδ inhibitor indicated for the treatment of relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other comorbidities.

Approval Statushttps://ashpublications.org/blood/article/128/3/331/35546/Idelalisib-in-the-management-of-lymphoma
Instructions for use:dosing, indications, interactions...etc.https://reference.medscape.com/drug/zydelig-idelalisib-999941
REFERENCE

Duvelisib[6]

Duvelisib is a prescription medicine used to treat adults with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) who have received at least 2 prior therapies and they did not work or are no longer working. It is not known if Duvelisib is safe and effective in children less than 18 years of age.

Approval Statushttps://medlineplus.gov/druginfo/meds/a618056.html
Instructions for use:dosing, indications, interactions...etc.https://reference.medscape.com/drug/copiktra-duvelisib-1000261
REFERENCE

Obinutuzumab[7]

GAZYVA® (obinutuzumab) is a prescription medicine used with the chemotherapy drug, chlorambucil, to treat chronic lymphocytic leukemia (CLL) in adults who have not had previous CLL treatment.

GAZYVA® (obinutuzumab) is a prescription medicine used with the chemotherapy drug, bendamustine, followed by GAZYVA alone for follicular lymphoma (FL) in adults who did not respond to a rituximab-containing regimen, or whose FL returned after such treatment.

GAZYVA® (obinutuzumab) is a prescription medicine used in combination with chemotherapy, followed by GAZYVA alone in those who responded, to treat stage II bulky, III, or IV follicular lymphoma (FL) in adults who have not had previous FL treatment.

Approval Statushttps://www.gene.com/patients/medicines/gazyva
Instructions for use:dosing, indications, interactions...etc.https://reference.medscape.com/drug/gazyva-obinutuzumab-999895
REFERENCE

Alemtuzumab[8]

Alemtuzumab is a medication used to treat chronic lymphocytic leukemia and multiple sclerosis. In CLL, it has been used as both a first line and second line treatment. In MS it is generally only recommended if other treatments have not worked.

Approval Statushttps://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(07)70365-0/fulltext
Instructions for use:dosing, indications, interactions...etc.https://reference.medscape.com/drug/campath-lemtrada-alemtuzumab-342240
REFERENCE

Link

Poster

Prev:This is the latest article

Next:


Top